Suchergebnisse
Suchergebnisse:
Find the latest Rigel Pharmaceuticals, Inc. (RIGL) stock quote, history, news and other vital information to help you with your stock trading and investing.
Vor 4 Tagen · RIGL | Rigel Pharmaceuticals Aktien News ☑ Mit Realtime Kurs, Dividende und Prognose der Rigel Pharmaceuticals Aktie Analysiere mit wallstreetONLINE.
RIGEL PHARMACEUTICALS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Rigel Pharmaceuticals IncShs | 766093 | RIGL | US7665596034
- Fairer Preis
- Negative Analystenhaltung seit 12.04.2024
- Negativer Markttrend seit dem 02.04.2024
- 766,1K
Rigel develops novel therapies for acute myeloid leukemia and chronic immune thrombocytopenia. Learn about its products REZLIDHIA and TAVALISSE, and its pipeline and clinical trials.
Vor 4 Tagen · News zur RIGEL PHARMACEUTICALS AKTIE und aktueller Realtime-Aktienkurs Earnings call: Rigel Pharmaceuticals Q1 2024 performance and outlook.
Unternehmen / AktienAktienkurs%Top-nachrichten27,630+0,16 %26,375-0,60 %124,78-0,97 %92,48-1,05 %- (3)
Get the latest Rigel Pharmaceuticals Inc (RIGL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
5. März 2024 · SOUTH SAN FRANCISCO, Calif., March 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2023, including sales of TAVALISSE ® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune ...